Combination of MRI and dynamic FET PET for initial glioma grading;Kombination von MRI und dynamischer FET-PET zum initialen Grading von Gliomen

NuklearMedizin

Volumn 53, Issue 4, 2014, Pages 155-161

  Dunet, Vincent ^a   Maeder, P ^a   Nicod Lalonde, M ^a   Lhermitte, B ^a   Pollo, C ^b   Bloch, J ^a   Stupp, R ^a   Meuli, R ^a   Prior, J O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

ADC histogram; Glioma; Grading; MRI

Indexed keywords

18F FLUORETHYLTYROSIN; GADOTERATE MEGLUMINE; GADOTERIC ACID; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (18F)FLUOROETHYLTYROSINE; TYROSINE;

ADULT; ARTICLE; BRAIN TUMOR; CANCER GRADING; CANCER SURGERY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; FEMALE; GLIOMA; HISTOGRAM; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MEASUREMENT ACCURACY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; STANDARDIZED UPTAKE VALUE; STEREOTACTIC BIOPSY; TARGET TO BACKGROUND RATIO; TIME ACTIVITY CURVE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DIAGNOSTIC USE; IMAGE ENHANCEMENT; MULTIMODAL IMAGING; OBSERVER VARIATION; PATHOLOGY; PROCEDURES; REPRODUCIBILITY;

ADULT; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; NEOPLASM GRADING; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TYROSINE;

EID: 84905499416     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0650-14-03     Document Type: Article

References (34)

1. Arvinda HR, Kesavadas C, Sarma PS et al. Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol 2009; 94: 87-96.
2. Baborie A, Kuschinsky W. Lack of relationship between cellular density and either capillary density or metabolic rate in different regions of the brain. Neurosci Lett 2006; 404: 20-22.
3. Bull JG, Saunders DE, Clark CA. Discrimination of paediatric brain tumours using apparent diffusion coefficient histograms. Eur Radiol 2012; 22: 447-457.
4. Calcagni ML, Galli G, Giordano A et al. Dynamic O-(2-[18 F]fluoroethyl)-L-tyrosine PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med 2011; 36: 841-847.
5. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neurooncology 2012; 14 (Suppl 5): v1-v49.
6. Dunet V, Rossier C, Buck A et al. Performance of 18F-fluoro-ethyl-tyrosine (18 F-FET) PET for the differential diagnosis of primary brain tumor. J Nucl Med. 2012; 53: 207-214.
7. Ellingson BM, Malkin MG, Rand SD et al. Validation of functional diffusion maps as a biomarker for human glioma cellularity. J Magn Reson Imaging 2010; 31: 538-548.
8. Floeth FW, Pauleit D, Wittsack HJ et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18 F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg 2005; 102: 318-327.
9. Heiss P, Mayer S, Herz M et al. Investigation of transport mechanism and uptake kinetics of O-(2-[18 F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999; 40: 1367-1373.
10. Heller IH, Elliott KA. The metabolism of normal brain and human gliomas in relation to cell type and density. Can J Biochem Physiol 1955; 33: 395-403.
11. Herzog H, Langen KJ, Weirich C et al. High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin 2011; 50: 74-82.
12. Holodny AI, Makeyev S, Beattie BJ et al. Apparent diffusion coefficient of glial neoplasms. AJNR Am J Neuroradiol 2010; 31: 1042-1048.
13. Jansen NL, Graute V, Armbruster L et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 2012; 39: 1021-1029.
14. Jansen NL, Schwartz C, Graute V et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [18 F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol 2012; 14: 1473-1480.
15. Kang Y, Choi SH, Kim YJ et al. Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard-or high-b-value diffusionweighted MR imaging--correlation with tumor grade. Radiology 2011; 261: 882-890.
16. Kunz M, Thon N, Eigenbrod S et al. Hot spots in dynamic 18 FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 2011; 13: 307-316.
17. La Fougere C, Suchorska B, Bartenstein P et al. Molecular imaging of gliomas with PET. Neuro Oncol 2011; 13: 806-819.
18. Langen KJ, Bartenstein P, Boecker H et al. German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids. Nuklearmedizin 2011; 50: 167-173.
19. Law M, Yang S, Wang H et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24: 1989-1998.
20. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
21. Moller-Hartmann W, Herminghaus S, Krings T et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002; 44: 371-381.
22. Palumbo B, Angotti F, Marano GD. Relationship between PET-FDG and MRI apparent diffusion coefficients in brain tumors. Q J Nucl Med Mol Imaging 2009; 53: 17-22.
23. Pauleit D, Floeth F, Hamacher K et al. O-(2-[18 F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005; 128: 678-687.
24. Pauleit D, Floeth F, Herzog H et al. Whole-body distribution and dosimetry of O-(2-[18 F]fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging. 2003; 30: 519-524.
25. Pope WB, Kim HJ, Huo J et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009; 252: 182-189.
26. Pöpperl G, Gotz C, Rachinger W et al. Value of O-(2-[18 F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004; 31: 1464-1470.
27. Pöpperl G, Kreth FW, Herms J et al. Analysis of 18 F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006; 47: 393-403.
28. Pöpperl G, Kreth FW, Mehrkens JH et al. FET PET for the evaluation of untreated gliomas. Eur J Nucl Med Mol Imaging 2007; 34: 1933-1942.
29. Rose S, Fay M, Thomas P et al. Correlation of MRI-derived apparent diffusion coefficients in newly diagnosed gliomas with [18 F]-fluoro-L-dopa PET. AJNR Am J Neuroradiol 2013; 34: 758-764.
30. Salber D, Stoffels G, Pauleit D et al. Differential uptake of O-(2-18 F-fluoroethyl)-L-tyrosine, L-3 H-methionine, and 3 H-deoxyglucose in brain abscesses. J Nucl Med 2007; 48: 2056-2062.
31. Spaeth N, Wyss MT, Weber B et al. Uptake of 18 F-fluorocholine, 18 F-fluoroethyl-L-tyrosine, and 18 F-FDG in acute cerebral radiation injury in the rat. J Nucl Med 2004; 45: 1931-1938.
32. Vander Borght T, Asenbaum S, Bartenstein P et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 2006; 33: 1374-1380.
33. Weber WA, Wester HJ, Grosu AL et al. O-(2-[18 F]fluoroethyl)-L-tyrosine and L-[methyl-11 C]methionine uptake in brain tumours. Eur J Nucl Med 2000; 27: 542-549.
34. Wester HJ, Herz M, Weber W et al. Synthesis and radiopharmacology of O-(2-[18 F]fluoroethyl)-Ltyrosine for tumor imaging. J Nucl Med 1999; 40: 205-212.